2013 Historical

Financial
Review
he Historical Financial Review is
prepared once per year and is
available on line at www.investor.jnj.com.
It is intended to supplement the Annual
Report and other SEC filings and be used
primarily by financial analysts to assist in a
detailed financial analysis. While this
document does include abbreviated
financial statements, it is not a substitute
for the more detailed financial statements
(including footnotes) found in the Annual
Report and other SEC filings.

We appreciate your comments and
suggestions on ways to improve this
document and will attempt to incorporate
them into future editions.









Index Page

T

Introduction 1
Five Year Selected Financial Data 2
Description of Major Business Franchises 3
Balance Sheets, Statements of Earnings, Statements of Cash Flows 4-6
Segments of Business Information 7-8
Geographical Areas 9
Sales Growth Rates 10
Quarterly Sales and Earnings Information 11-14
Sales and Net Earnings 1887-2013 15
Stock Split and Share Repurchase Information 16
Common Stock Information 1944-2013 17-18
Reconciliation of Non-GAAP Measures 19
Corporate and Shareholder/Investor Information 20

Historical Financial Review
1
Johnson & Johnson and Subsidiaries:
Five-Year Selected Financial Data 2009-2013
(Dollars in Millions Except Per Share Figures)
Operating Results 2013
(1)
2012
(1)
2011
(1)
2010
(1)
2009
(1)
Sales to customers 71,312 $ 67,224 65,030 61,587 61,897
Earnings before provision for taxes on income 15,471 13,775 12,361 16,947 15,755
Net earnings attributable to J &J
(2)
13,831 10,853 9,672 13,334 12,266
Basic net earnings per share 4.92 $ 3.94 3.54 4.85 4.45
Diluted net earnings per share 4.81 $ 3.86 3.49 4.78 4.40
Statistics
Before tax margin 21.7 % 20.5 19.0 27.5 25.4
Net profit margin
(2)
19.4 16.1 14.9 21.7 19.8
Effective tax rate 10.6 23.7 21.8 21.3 22.1
Return on average shareholders' equity 19.9 17.8 17.0 24.9 26.4
Return on total assets 10.4 % 8.9 8.5 13.0 13.0
Capital Structure
Cash and Current Marketable Securities 29,206 $ 21,089 32,261 27,658 19,425
Debt 18,180 16,165 19,627 16,773 14,541
Equity 74,053 64,826 57,080 56,579 50,588
Total capital 92,233 80,991 76,707 73,352 65,129
Net cash/(debt) 11,026 $ 4,924 12,634 10,885 4,884
Total debt/total capital 19.7 % 20.0 25.6 22.9 22.3
Common Stock Information
Dividends paid per share 2.590 $ 2.400 2.250 2.110 1.930
Shareholders' equity per share 26.25 $ 23.33 20.95 20.66 18.37
Market price per share (year end close) 92.35 $ 69.48 65.58 61.85 64.41
Average shares outstanding (mm) - basic 2,809.2 2,753.3 2,736.0 2,751.4 2,759.5
- diluted 2,877.0 2,812.6 2,775.3 2,788.8 2,789.1
Cash dividends 7,286 $ 6,614 6,156 5,804 5,327
Other Data
Total assets 132,683 $ 121,347 113,644 102,908 94,682
Research & development expense 8,183 7,665 7,548 6,844 6,986
Capital expenditures 3,595 $ 2,934 2,893 2,384 2,365
Number of employees (thousands) 128.1 127.6 117.9 114.0 115.5
(1) For Adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 19.
(2) After noncontrolling interests
2


Consumer Segment
The Consumer segment includes a broad range of
products used in the baby care, skin care, oral care,
wound care and women's health care fields, as well as
nutritional and over-the-counter pharmaceutical
products and wellness and prevention platforms.
These products are marketed to the general public and
sold both to retail outlets and distributors throughout
the world.

The Baby Care franchise includes the J OHNSONS

Baby line of products. Major brands in the Skin Care
franchise include the AVEENO

; CLEAN & CLEAR

;
J OHNSONS

Adult; NEUTROGENA

; RoC

;
LUBRIDERM

; and DABAO
TM
product lines. The Oral
Care franchise includes the LISTERINE

oral care lines.

The Wound Care franchise includes BAND-AID

brand
adhesive bandages and NEOSPORIN

First Aid
products. Major brands in the Womens Health
franchise outside of North America are CAREFREE

Pantiliners; o.b.

tampons and STAYFREE

sanitary
protection products. The principal nutritional line is
SPLENDA

No Calorie Sweetener. Over-the-counter

medicines include the broad family of TYLENOL

acetaminophen products; SUDAFED

cold, flu and

allergy products; ZYRTEC

allergy products; MOTRIN

IB ibuprofen products; and PEPCID

AC

Acid
Controller.

Medical Devices and Diagnostics Segment
The Medical Devices & Diagnostics segment includes a
broad range of products distributed to wholesales,
hospitals and retailers, used principally in the
professional fields by physicians, nurses, hospitals and
clinics. These include products to treat cardiovascular
disease; orthopaedic and neurological products; blood
glucose monitoring and insulin delivery products;
general surgery, biosurgical, and energy products;
professional diagnostic products; infection prevention
products; and disposable contact lenses.











Pharmaceutical Segment
The Pharmaceutical segment includes products in the
following therapeutic areas: anti-infective, antipsychotic,
cardiovascular, contraceptive, gastrointestinal, hema-
tology, immunology, infectious diseases, metabolic,
neurology, oncology, pain management and vaccines.
These products are distributed directly to retailers,
wholesalers and health care professionals for
prescription use.

Key products in the Pharmaceutical segment include:
REMICADE

(infliximab), a treatment for a number of

immune-mediated inflammatory diseases;
SIMPONI

(golimumab), a treatment for adults with

moderate to severe rheumatoid arthritis, active psoriatic
arthritis, active ankylosing spondylitis and moderately
active to severely active ulcerative colitis;
STELARA

(ustekinumab), a treatment for adults with

moderate to severe plaque psoriasis and active psoriatic
arthritis; INCIVO

(telaprevir), for the treatment of

hepatitis C; INTELENCE

(etravirine) and
PREZISTA

(darunavir), treatments for HIV/AIDS;

CONCERTA

(methylphenidate HCl) extended-release

tablets CII, a treatment for attention deficit hyperactivity
disorder; INVEGA

(paliperidone) extended-release
tablets, for the treatment of schizophrenia and
schizoaffective disorder;
INVEGA

SUSTENNA

/XEPLION

(paliperidone
palmitate), for the treatment of schizophrenia in adults;
RISPERDAL

CONSTA

(risperidone), for the treatment

of schizophrenia and for the maintenance treatment of
Bipolar I Disorder; VELCADE

(bortezomib), a treatment
for multiple myeloma; ZYTIGA

(abiraterone acetate), a
treatment for metastatic castration-resistant prostate
cancer; ACIPHEX

/PARIET

, a proton pump inhibitor

co-marketed with Eisai Inc.; PROCRIT

(epoetin alfa,
sold outside the U.S. as EPREX

), to stimulate red blood

cell production; and XARELTO

(rivaroxaban), an oral
anticoagulant for the prevention of deep vein thrombosis
(DVT), which may lead to pulmonary embolism (PE) in
patients undergoing hip or knee replacement surgery, to
reduce the risk of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation, for the
treatment of DVT and PE, and for the reduction in the
risk of recurrence of DVT and PE.

Newly launched products in the Pharmaceutical segment
include: INVOKANA

(canagliflozin), a treatment for type

2 diabetes; OLYSIO
TM
(simeprevir), for the treatment of
chronic hepatitis C; and IMBRUVICA
TM
(Ibrutinib), for the
treatment of mantle cell lymphoma.
Description of Major Business Franchises

3
Johnson & Johnson and Subsidiaries:
Consolidated Balance Sheets (Dollars in Millions)
Assets 2013 2012 2011
Current assets
Cash and cash equivalents 20,927 $ 14,911 24,542
Marketable securities 8,279 6,178 7,719
Accounts receivable trade, less allowance for doubtful accounts 11,713 11,309 10,581
Inventories 7,878 7,495 6,285
Other current assets 7,610 6,223 5,189
Total current assets 56,407 46,116 54,316
Property, plant and equipment, net 16,710 16,097 14,739
Intangible assets, net and Goodwill 50,745 51,176 34,276
Other non-current assets 8,821 7,958 10,313
Total assets 132,683 $ 121,347 113,644
Liabilities and Shareholders' Equity
Current liabilities
Loans and notes payable 4,852 $ 4,676 6,658
Accounts payable 6,266 5,831 5,725
Accrued liabilities 13,787 12,691 9,574
Accrued taxes on income 770 1,064 854
Total current liabilities 25,675 24,262 22,811
Long-term debt 13,328 11,489 12,969
Other long-term liabilities 19,627 20,770 20,784
Total liabilities 58,630 56,521 56,564
Shareholders' equity
Common stock 3,120 3,120 3,120
Accumulated other comprehensive income (2,860) (5,810) (5,632)
Retained earnings 89,493 85,992 81,251
89,753 83,302 78,739
Less: common stock held in treasury, at cost 15,700 18,476 21,659
Total shareholders' equity 74,053 $ 64,826 57,080
Total liabilities and shareholders' equity 132,683 $ 121,347 113,644
4
Johnson & Johnson and Subsidiaries:
Consolidated Statements of Earnings (Dollars in Millions Except Per Share Figures)
2013
(1)
2012
(1)
2011
(1)
2010
(1)
2009
(1)
Sales to customers 71,312 $ 67,224 $ 65,030 $ 61,587 $ 61,897 $
Cost of products sold 22,342 21,658 20,360 18,792 18,447
Gross profit 48,970 45,566 44,670 42,795 43,450
Selling, marketing and administrative expenses 21,830 20,869 20,969 19,424 19,801
Research and development expense 8,183 7,665 7,548 6,844 6,986
In-process research and development 580 1,163 - - -
Interest income (74) (64) (91) (107) (90)
Interest expense, net of portion capitalized 482 532 571 455 451
Other (income) expense, net 2,498 1,626 2,743 (768) (526)
Restructuring - - 569 - 1,073
Earnings before provision for taxes on income 15,471 13,775 12,361 16,947 15,755
Provision for taxes on income 1,640 3,261 2,689 3,613 3,489
Net earnings 13,831 10,514 9,672 13,334 12,266
Add: Net loss attributable to noncontrolling interests - 339 - - -
Net earnings attributable to Johnson & Johnson 13,831 10,853 9,672 13,334 12,266
Basic net earnings per share attributable to J&J 4.92 $ 3.94 $ 3.54 $ 4.85 $ 4.45 $
Diluted net earnings per share attributable to J&J 4.81 $ 3.86 $ 3.49 $ 4.78 $ 4.40 $
Ratios to Sales
Sales to customers 100.0% 100.0% 100.0% 100.0% 100.0%
Cost of products sold 31.3 32.2 31.3 30.5 29.8
Gross profit 68.7 67.8 68.7 69.5 70.2
Selling, marketing & administrative expense 30.6 31.0 32.3 31.5 32.0
Research expense 11.5 11.4 11.6 11.1 11.3
Earnings before provision for taxes on income 21.7 20.5 19.0 27.5 25.4
Provision for taxes on income 2.3 4.9 4.1 5.8 5.6
Net earnings attributable to J ohnson & J ohnson 19.4 16.1 14.9 21.7 19.8
(1) For Adjusted earnings (before and after tax) and adjusted earnings per share, see Reconciliation of Non-GAAP Measures on Page 19.
5
Johnson & Johnson and Subsidiaries:
Consolidated Statements of Cash Flows (Dollars in Millions)
2013 2012 2011
Cash flows from operations
Net earnings 13,831 $ 10,514 9,672
Adjustments to reconcile net earnings to cash flows:
Depreciation and amortization of property and intangibles 4,104 3,666 3,158
Stock Based Compensation 728 662 621
Noncontrolling interest - 339 -
Venezuela currency devaluation 108 - -
Asset write-downs 739 2,131 160
Net gain on equity investment transactions (417) - -
Deferred tax provision (607) (39) (836)
Accounts receivable allowances (131) 92 32
Changes in assets and liabilities, net of effects from acquisitions:
(Increase)/Decrease in accounts receivable (632) (9) (915)
(Increase)/Decrease in inventories (622) (1) (715)
Increase/(Decrease) in accounts payable and accrued liabilities 1,821 2,768 493
(Increase)/Decrease in other current and non-current assets (1,806) (2,172) (1,785)
Increase/(Decrease) in other current and non-current liabilities 298 (2,555) 4,413
Net cash flows from operating activities 17,414 15,396 14,298
Cash flows from investing activities
Additions to property, plant and equipment (3,595) (2,934) (2,893)
Proceeds from the disposal of assets 458 1,509 1,342
Acquisitions, net of cash acquired (835) (4,486) (2,797)
Purchases of investments (18,923) (13,434) (29,882)
Sales of investments 18,058 14,797 30,396
Other (266) 38 (778)
Net cash used by investing activities (5,103) (4,510) (4,612)
Cash flows from financing activities
Dividends to shareholders (7,286) (6,614) (6,156)
Repurchase of common stock (3,538) (12,919) (2,525)
Proceeds from short-term debt 1,411 3,268 9,729
Retirement of short-term debt (1,397) (6,175) (11,200)
Proceeds from long-term debt 3,607 45 4,470
Retirement of long-term debt (1,593) (804) (16)
Proceeds from the exercise of stock options/excess tax benefits 2,649 2,720 1,246
Other 56 (83) -
Net cash used by financing activities (6,091) (20,562) (4,452)
Effect of exchange rate changes on cash and cash equivalents (204) 45 (47)
Increase/(Decrease) in cash and cash equivalents 6,016 (9,631) 5,187
Cash and cash equivalents, beginning of year 14,911 24,542 19,355
Cash and cash equivalents, end of year 20,927 $ 14,911 24,542
Supplemental cash flow data
Cash paid during the year for:
Interest 596 $ 616 576
Interest, net of amount capitalized 491 $ 501 492
Income taxes 3,155 2,507 2,970
Supplemental schedule of noncash investing and financing activities
Issuance of common stock associated with the acquisition of Synthes, Inc. - $ 13,335 -
Treasury stock issued for employee compensation and stock option plans,
net of cash proceeds 743 615 433
Conversion of debt 22 - 1
Acquisition of businesses
Fair value of assets acquired 1,028 $ 19,025 3,025
Fair value of liabilities assumed and noncontrolling interests (193) (1,204) (228)
Net fair value of acquisitions 835 $ 17,821 2,797
Less: Issuance of common stock associated with the acquisition of Synthes, Inc. - 13,335 -
Net cash paid for acquisitions 835 $ 4,486 2,797
6
Johnson & Johnson and Subsidiaries:
Segments of Business (Dollars in Millions)
Sales to Customers 2013
(1)
2012
(2)
2011
(3)
2010
(4)
2009
(5)
Consumer
United States 5,162 $ 5,046 5,151 5,519 6,837
International 9,535 9,401 9,732 9,071 8,966
Total 14,697 14,447 14,883 14,590 15,803
Pharmaceutical
United States 13,948 12,421 12,386 12,519 13,041
International 14,177 12,930 11,982 9,877 9,479
Total 28,125 25,351 24,368 22,396 22,520
Medical Devices and Diagnostics
United States 12,800 12,363 11,371 11,412 11,011
International 15,690 15,063 14,408 13,189 12,563
Total 28,490 27,426 25,779 24,601 23,574
Worldwide
United States 31,910 29,830 28,908 29,450 30,889
International 39,402 37,394 36,122 32,137 31,008
Total 71,312 $ 67,224 65,030 61,587 61,897
Pre-Tax Profit
Consumer 1,973 $ 1,693 2,096 2,342 2,475
Pharmaceutical 9,178 6,075 6,406 7,086 6,413
Medical Devices and Diagnostics 5,261 7,187 5,263 8,272 7,694
Segments Total 16,412 14,955 13,765 17,700 16,582
Less: Expenses/(Income) not allocated to segments
(6)
941 1,180 1,404 753 827
Worldwide Total 15,471 $ 13,775 12,361 16,947 15,755
Pre-Tax Profit as % of Segment Sales
Consumer 13.4% 11.7% 14.1% 16.1% 15.7%
Pharmaceutical 32.6% 24.0% 26.3% 31.6% 28.5%
Medical Devices and Diagnostics 18.5% 26.2% 20.4% 33.6% 32.6%
Segments Total 23.0% 22.2% 21.2% 28.7% 26.8%
Worldwide Total 21.7% 20.5% 19.0% 27.5% 25.4%
Identifiable Assets
Consumer 23,711 $ 24,131 24,210 23,753 24,671
Pharmaceutical 23,783 23,219 23,747 19,961 21,460
Medical Devices and Diagnostics 44,585 42,926 23,609 23,277 22,853
Segments Total 92,079 90,276 71,566 66,991 68,984
General corporate
(7)
40,604 31,071 42,078 35,917 25,698
Worldwide Total 132,683 $ 121,347 113,644 102,908 94,682
(7) General corporate includes cash & marketable securities.
(6) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2
billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.
(1) 2013 pre-tax profit includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Diagnostics and
Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes
$580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics
segments, respectively. The Medical Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASR
TM
Hip
program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments,
respectively.
(2) 2012 pre-tax profit includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and
Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the
Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices
and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the
Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million
expense for the cost associated with the DePuy ASR Hip program.
(3) 2011 pre-tax profit includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and
Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics
segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost
associated with the DePuy ASR Hip program.
(4) 2010 pre-tax profit includes $397 million of net litigation gain comprised of $447 million expense in the Pharmaceutical segment and a gain of $844 million in the
Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy
ASR Hip program.
(5) 2009 pre-tax profit includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical,
and Medical Devices and Diagnostics segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the
Pharmaceutical segment and a gain of $478 million in the Medical Devices and Diagnostics segment.
7
Johnson & Johnson and Subsidiaries:
Segments of Business (Dollars in Millions)
Additions to Property, Plant and Equipment 2013 2012 2011 2010 2009
Consumer 533 $ 468 670 526 439
Pharmaceutical 856 737 729 508 535
Medical Devices and Diagnostics 1,724 1,230 1,095 1,113 1,114
Segments Total 3,113 2,435 2,494 2,147 2,088
General corporate 482 499 399 237 277
Worldwide Total 3,595 $ 2,934 2,893 2,384 2,365
Depreciation & Amortization
Consumer 539 $ 575 631 532 513
Pharmaceutical 1,075 1,010 958 912 922
Medical Devices and Diagnostics 2,224 1,857 1,331 1,270 1,124
Segments Total 3,838 3,442 2,920 2,714 2,559
General corporate 266 224 238 225 215
Worldwide Total 4,104 $ 3,666 3,158 2,939 2,774
Research Expense and Development
Consumer segment 590 $ 622 659 609 632
Pharmaceutical segment 5,810 5,362 5,138 4,432 4,591
Med Devices and Diagnostics segments 1,783 1,681 1,751 1,803 1,763
Worldwide total 8,183 $ 7,665 7,548 6,844 6,986
Research Expense as a Percent of Segment Sales
Consumer segment 4.0% 4.3% 4.4% 4.2% 4.0%
Pharmaceutical segment 20.7% 21.2% 21.1% 19.8% 20.4%
Med Devices and Diagnostics segments 6.3% 6.1% 6.8% 7.3% 7.5%
Worldwide total 11.5% 11.4% 11.6% 11.1% 11.3%
Pharmaceutical Research Expense as a Percent of
total J&J WW Sales 8.1% 8.0% 7.9% 7.2% 7.4%
8
Johnson & Johnson and Subsidiaries:
Geographical Areas (Dollars in Millions)
Sales to Customers 2013 2012 2011 2010 2009
United States 31,910 $ 29,830 28,908 29,450 30,889
Europe 18,599 16,945 17,129 15,510 15,934
Western Hemisphere excluding U.S. 7,421 7,207 6,418 5,550 5,156
Asia-Pacific, Africa 13,382 13,242 12,575 11,077 9,918
Total 71,312 $ 67,224 65,030 61,587 61,897
Long-Lived Assets
United States 35,880 $ 35,115 23,529 23,315 22,399
Europe 24,868 25,261 19,056 16,791 17,347
Western Hemisphere excluding U.S. 3,281 3,636 3,517 3,653 3,540
Asia-Pacific, Africa 2,434 2,362 2,163 2,089 1,868
Segments total 66,463 66,374 48,265 45,848 45,154
General corporate 992 899 750 715 790
Other non long-lived assets 65,228 54,074 64,629 56,345 48,738
Worldwide total 132,683 $ 121,347 113,644 102,908 94,682
9
Johnson & Johnson and Subsidiaries:
Sales Growth Rates
2013 2012 2011 2010 2009
United States 7.0% 3.2% -1.8% -4.7% -4.4%
Operations 7.0% 3.2% -1.8% -4.7% -4.4%
International 5.4% 3.5% 12.4% 3.6% -1.4%
Operations 8.2% 8.4% 7.0% 1.9% 3.9%
Currency -2.8% -4.9% 5.4% 1.7% -5.3%
Worldwide 6.1% 3.4% 5.6% -0.5% -2.9%
Operations 7.7% 6.1% 2.8% -1.3% -0.3%
Currency -1.6% -2.7% 2.8% 0.8% -2.6%
Compound Growth Rates
United States International Worldwide
2008-2013 (5 Yr.) -0.2% 4.6% 2.3%
2003-2013 (10 Yr.) 2.4% 9.0% 5.5%
10
Johnson & Johnson and Subsidiaries:
Quarterly Sales by Segment (Dollars in Millions)
Year U.S. Int'l WW U.S. Int'l WW
1Q 2009 1,726 1,985 3,711 3,674 2,106 5,780
2Q 2009 1,708 2,146 3,854 3,172 2,326 5,498
3Q 2009 1,691 2,298 3,989 2,857 2,392 5,249
4Q 2009 1,712 2,537 4,249 3,338 2,655 5,993
2009 6,837 8,966 15,803 13,041 9,479 22,520
1Q 2010 1,560 2,206 3,766 3,206 2,432 5,638
2Q 2010 1,463 2,184 3,647 3,110 2,443 5,553
3Q 2010 1,277 2,290 3,567 3,054 2,441 5,495
4Q 2010 1,219 2,391 3,610 3,149 2,561 5,710
2010 5,519 9,071 14,590 12,519 9,877 22,396
1Q 2011 1,345 2,337 3,682 3,391 2,668 6,059
2Q 2011 1,339 2,454 3,793 3,239 2,994 6,233
3Q 2011 1,219 2,521 3,740 2,869 3,113 5,982
4Q 2011 1,248 2,420 3,668 2,887 3,207 6,094
2011 5,151 9,732 14,883 12,386 11,982 24,368
1Q 2012 1,316 2,279 3,595 3,026 3,107 6,133
2Q 2012 1,313 2,306 3,619 3,094 3,197 6,291
3Q 2012 1,214 2,367 3,581 3,288 3,114 6,402
4Q 2012 1,203 2,449 3,652 3,013 3,512 6,525
2012 5,046 9,401 14,447 12,421 12,930 25,351
1Q 2013 1,348 2,327 3,675 3,471 3,297 6,768
2Q 2013 1,326 2,332 3,658 3,377 3,648 7,025
3Q 2013 1,225 2,386 3,611 3,549 3,487 7,036
4Q 2013 1,263 2,490 3,753 3,551 3,745 7,296
2013 5,162 9,535 14,697 13,948 14,177 28,125
Consumer Pharmaceutical
11
Johnson & Johnson and Subsidiaries:
Quarterly Sales by Segment (Dollars in Millions)
Year U.S. Int'l WW U.S. Int'l WW
1Q 2009 2,652 2,883 5,535 8,052 6,974 15,026
2Q 2009 2,776 3,111 5,887 7,656 7,583 15,239
3Q 2009 2,766 3,077 5,843 7,314 7,767 15,081
4Q 2009 2,817 3,492 6,309 7,867 8,684 16,551
2009 11,011 12,563 23,574 30,889 31,008 61,897
1Q 2010 2,886 3,341 6,227 7,652 7,979 15,631
2Q 2010 2,865 3,265 6,130 7,438 7,892 15,330
3Q 2010 2,800 3,120 5,920 7,131 7,851 14,982
4Q 2010 2,861 3,463 6,324 7,229 8,415 15,644
2010 11,412 13,189 24,601 29,450 32,137 61,587
1Q 2011 2,872 3,560 6,432 7,608 8,565 16,173
2Q 2011 2,869 3,702 6,571 7,447 9,150 16,597
3Q 2011 2,780 3,503 6,283 6,868 9,137 16,005
4Q 2011 2,850 3,643 6,493 6,985 9,270 16,255
2011 11,371 14,408 25,779 28,908 36,122 65,030
1Q 2012 2,877 3,534 6,411 7,219 8,920 16,139
2Q 2012 2,953 3,612 6,565 7,360 9,115 16,475
3Q 2012 3,289 3,780 7,069 7,791 9,261 17,052
4Q 2012 3,244 4,137 7,381 7,460 10,098 17,558
2012 12,363 15,063 27,426 29,830 37,394 67,224
1Q 2013 3,206 3,856 7,062 8,025 9,480 17,505
2Q 2013 3,243 3,951 7,194 7,946 9,931 17,877
3Q 2013 3,151 3,777 6,928 7,925 9,650 17,575
4Q 2013 3,200 4,106 7,306 8,014 10,341 18,355
2013 12,800 15,690 28,490 31,910 39,402 71,312
Medical Devices and Diagnostics Total
12
Johnson & Johnson and Subsidiaries:
Quarterly Statement of Earnings
(1)
(Dollars in Millions except per share figures)
Year Sales
Cost of
Products Sold SM&A R&D
In-process
Research and
Development
Net Interest
Exp. (Inc.)
Other Exp.
(Inc.)
1Q 2013 17,505 $ 5,554 $ 5,223 $ 1,784 $ 64 $ 104 $ 515 $
2Q 2013 17,877 5,489 5,376 1,946 - 101 172
3Q 2013 17,575 5,344 5,314 2,042 178 87 943
4Q 2013 18,355 5,955 5,917 2,411 338 116 868
2013 71,312 $ 22,342 $ 21,830 $ 8,183 $ 580 $ 408 $ 2,498 $
Year Sales
Cost of
Products Sold Gross Margin SM&A R&D
In-process
Research and
Development
Net Interest
Exp. (Inc.)
1Q 2013 100.0% 31.7% 68.3% 29.8% 10.2% 0.4% 0.6%
2Q 2013 100.0% 30.7% 69.3% 30.1% 10.9% 0.0% 0.6%
3Q 2013 100.0% 30.4% 69.6% 30.2% 11.6% 1.0% 0.5%
4Q 2013 100.0% 32.5% 67.5% 32.2% 13.1% 1.9% 0.6%
2013 100.0% 31.3% 68.7% 30.6% 11.5% 0.8% 0.6%
(1) Net Earnings are GAAP and therefore, do not exclude special items.
Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Full Year Adjusted Earnings
Quarterly Statement of Earnings - as a % of Sales
13
Johnson & Johnson and Subsidiaries:
Quarterly Statement of Earnings (Continued)
(1)
(Dollars in Millions except per share figures)
Year
Total Cost &
Expense
Earnings
Before Taxes
Provision
for/(Benefit
from) Taxes
on Income Net Earnings
Basic
Earnings per
Share
Basic
Average
Shares
Diluted
Earnings per
Share
Diluted
Average
Shares
1Q 2013 13,244 $ 4,261 $ 764 $ 3,497 $ 1.25 $ 2,790.2 1.22 $ 2,858.8
2Q 2013 13,084 4,793 960 3,833 1.36 2,809.7 1.33 2,893.0
3Q 2013 13,908 3,667 685 2,982 1.06 2,818.4 1.04 2,881.2
4Q 2013 15,605 2,750 (769) 3,519 1.25 2,821.1 1.23 2,872.0
2013 55,841 $ 15,471 $ 1,640 $ 13,831 $ 4.92 $ 2,809.2 4.81 $ 2,877.0
Year
Other Exp.
(Inc.)
Total Cost &
Expense
Earnings
Before Taxes
Provision
for/(Benefit
from) Taxes
on Income
Income Taxes
(Eff. Rate) Net Earnings
1Q 2013 3.0% 75.7% 24.3% 4.3% 17.9% 20.0%
2Q 2013 0.9% 73.2% 26.8% 5.4% 20.0% 21.4%
3Q 2013 5.4% 79.1% 20.9% 3.9% 18.7% 17.0%
4Q 2013 4.7% 85.0% 15.0% -4.2% -28.0% 19.2%
2013 3.5% 78.3% 21.7% 2.3% 10.6% 19.4%
(1) Net Earnings are GAAP and therefore, do not exclude special items.
Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Full Year Adjusted Earnings
Quarterly Statement of Earnings - as a % of Sales
14
Johnson & Johnson and Subsidiaries:
Sales and Net Earnings
(2)
1887 - 2013
(1)
(Dollars in Millions)
Year
Net Trade
Sales
Net
Earnings Year
Net Trade
Sales
Net
Earnings Year
Net Trade
Sales (1) Net Earnings
1931 17.4 1.3 1976 2,522.5 205.4
1887 0.1 $ 1932 15.2 1.1 1977 2,914.1 247.3
1888 0.2 1933 17.1 0.9 1978 3,497.3 299.1
1889 0.3 1934 20.7 1.0 1979 4,211.6 352.1
1890 0.4 1935 24.7 1.3 1980 4,837.4 400.7
1891 0.4 1936 28.9 2.1 1981 5,399.0 467.6
1892 0.5 1937 32.3 1.7 1982 5,760.9 473.0
1893 0.5 1938 33.4 2.7 1983 5,972.9 489.0
1894 0.6 1939 35.1 3.7 1984 6,124.5 514.5
1895 0.6 1940 39.1 2.4 1985 6,421.3 613.7
1896 0.7 1941 56.6 3.2 1986 7,003.0 330.0
1897 0.7 0.19 $ 1942 78.2 2.8 1987 8,011.5 833.0
1898 0.9 0.13 1943 93.1 3.1 1988 8,999.5 974.0
1899 1.1 0.20 1944 93.6 3.1 1989 9,829.0 1,082.0
1900 1.3 0.23 1945 96.0 3.1 1990 11,365.0 1,080.0
1901 1.4 0.23 1946 112.6 8.3 1991 12,210.0 1,270.0
1902 1.6 0.27 1947 152.3 9.9 1992 13,600.0 977.0
1903 1.8 0.28 1948 165.6 12.1 1993 13,877.0 1,786.0
1904 2.0 0.36 1949 168.3 10.0 1994 15,454.0 1,961.0
1905 2.4 0.33 1950 195.5 15.7 1995 18,537.0 2,416.0
1906 2.7 0.53 1951 227.6 12.3 1996 21,387.0 2,942.0
1907 3.0 0.77 1952 232.2 8.8 1997 22,522.0 3,070.0
1908 2.9 0.54 1953 236.1 11.2 1998 23,811.0 3,024.0
1909 3.2 0.63 1954 243.5 12.2 1999 27,357.0 4,133.0
1910 3.9 0.67 1955 267.5 14.0 2000 29,172.0 4,764.0
1911 4.4 0.54 1956 293.6 15.6 2001 32,317.0 5,405.0
1912 4.6 1.05 1957 315.6 16.9 2002 36,298.0 6,277.0
1913 4.8 0.75 1958 321.2 15.1 2003 41,862.0 6,848.0
1914 5.0 0.63 1959 368.4 19.7 2004 47,348.0 8,180.0
1915 5.1 0.74 1960 384.4 20.2 2005 50,514.0 10,060.0
1916 6.2 1.11 1961 414.5 17.7 2006 53,324.0 11,053.0
1917 9.6 1.22 1962 447.6 19.9 2007 61,095.0 10,576.0
1918 13.7 1.37 1963 462.4 21.5 2008 63,747.0 12,949.0
1919 11.2 0.83 1964 503.3 26.8 2009 61,897.0 12,266.0
1920 15.2 0.50 1965 576.0 34.4 2010 61,587.0 13,334.0
1921 12.5 1.30 1966 660.6 40.1 2011 65,030.0 9,672.0
1922 13.7 1.90 1967 712.3 45.9 2012 67,224.0 10,853.0
1923 15.5 1.80 1968 801.3 57.6 2013 71,312.0 $ 13,831.0 $
1924 16.0 1.80 1969 901.9 69.4
1925 16.2 2.10 1970 1,002.0 83.7
1926 16.5 2.00 1971 1,140.5 101.8
1927 16.8 1.50 1972 1,317.7 120.7
1928 18.4 0.80 1973 1,611.8 148.4
1929 19.9 1.60 1974 1,937.2 161.6
1930 18.7 1.20 1975 2,224.7 183.8
(1) Sales restated for EITF change for 1991-2001 only. Net Earnings restated for FAS 123R Share Based Payment for 1996-2005.
(2) Net Earnings attributable to Johnson & Johnson.
Note: 1887-1989 information not restated and may include estimates.
Refer to Page 19, Reconciliation of Non-GAAP Measures, for an analysis of 2009-2013 Adjusted Earnings.
Note: Net Earnings are reported according to GAAP and therefore do not exclude special items.
15
Johnson & Johnson and Subsidiaries:
Stock Split and Share Repurchase Information (Dollars in Millions)
Stock Splits
Pay Out Date Action
May 5, 1947 100% Stock Dividend
November 15, 1948 5% Stock Dividend
November 15, 1949 5% Stock Dividend
March 20, 1951 5% Stock Dividend
J anuary 9, 1959 2 1/2 for 1 Split
J une 19, 1967 200% Stock Dividend
May 15, 1970 3 for 1 Split
May 18, 1981 3 for 1 Split
May 10, 1989 2 for 1 Split
J une 9, 1992 2 for 1 Split
J une 11, 1996 2 for 1 Split
J une 12, 2001 2 for 1 Split
Share Repurchase Program*
Total Shares Total Value Avg. Price
Year (Millions) (Dollars in Millions) Per Share
1984 160.0 $329 $2.0550
1986 160.0 670 4.1865
1988 97.8 500 5.1230
1992 42.4 500 11.7975
1993 49.6 500 10.0625
2002 83.6 5,000 59.7994
2006 81.8 5,000 61.1247
2007 55.8 3,600 64.5870
2008 69.1 4,500 65.1230
2009 15.5 800 51.6129
2010 17.9 $1,100 $61.4525
* Total value may be rounded. In addition, the Company repurchases shares annually for use in employee stock option and
employee incentive plans. In 1990, the Company repurchased 12.8 million shares for a total value of $100 million in connection with
the establishment of an ESOP. All shares and average price per share have been adjusted for stock split.
16
Johnson & Johnson and Subsidiaries:
Common Stock Information 1944-2013 (Price per share/Shares in Millions)
YEARLY YEARLY YEARLY YEAR-END YEARLY NET SHARES P/E
YEAR HIGH LOW AVERAGE PRICE DIVIDEND OUTSTANDING* RATIO
9/25/44 (open) $ 0.02 2,213.6
1944 $ 0.02 $ 0.01 $ 0.02 0.01 $ 0.00008 2,213.6 10
1945 0.03 0.02 0.02 0.02 0.00012 2,242.7 19
1946 0.03 0.02 0.02 0.03 0.00012 2,264.0 7
1947 0.03 0.02 0.03 0.02 0.00020 2,276.0 6
1948 0.03 0.03 0.03 0.03 0.00067 2,243.1 6
1949 0.05 0.03 0.03 0.05 0.00115 2,247.9 12
1950 0.07 0.04 0.05 0.07 0.00176 2,260.2 12
1951 0.08 0.06 0.07 0.06 0.00102 2,264.1 18
1952 0.07 0.05 0.06 0.06 0.00093 2,259.8 15
1953 0.06 0.05 0.06 0.06 0.00152 2,268.4 15
1954 0.07 0.06 0.06 0.07 0.00152 2,274.9 17
1955 0.08 0.06 0.07 0.07 0.00152 2,270.4 15
1956 0.08 0.06 0.07 0.07 0.00152 2,276.6 12
1957 0.09 0.07 0.08 0.08 0.00167 2,288.0 14
1958 0.14 0.08 0.11 0.12 0.00157 2,290.3 22
1959 0.17 0.11 0.16 0.14 0.00185 2,558.8 23
1960 0.18 0.13 0.16 0.17 0.00231 2,563.5 28
1961 0.26 0.17 0.22 0.24 0.00231 2,586.3 31
1962 0.26 0.14 0.22 0.17 0.00231 2,584.8 24
1963 0.29 0.17 0.24 0.24 0.00255 2,591.9 29
1964 0.28 0.22 0.25 0.26 0.00278 2,574.6 27
1965 0.40 0.26 0.35 0.40 0.00336 2,603.0 32
1966 0.47 0.32 0.41 0.40 0.00382 2,588.2 28
1967 0.67 0.38 0.50 0.64 0.00428 2,606.1 33
1968 0.75 0.52 0.63 0.74 0.00451 2,619.4 34
1969 1.26 0.70 0.99 1.25 0.00590 2,656.4 41
1970 1.25 0.89 1.06 1.19 0.00708 2,676.3 43
1971 2.08 1.18 1.74 2.05 0.00896 2,690.8 54
1972 2.77 1.96 2.50 2.72 0.00932 2,708.1 59
1973 2.76 2.11 2.47 2.35 0.01094 2,761.1 41
1974 2.49 1.52 1.97 1.69 0.01510 2,773.6 28
1975 2.08 1.51 1.85 1.87 0.01771 2,785.7 30
1976 2.01 1.49 1.84 1.63 0.02188 2,796.1 22
1977 1.63 1.30 1.46 1.60 0.02917 2,808.3 16
1978 1.86 1.37 1.61 1.54 0.03542 2,872.9 14
1979 1.68 1.35 1.52 1.65 0.04167 2,938.2 12
1980 2.11 1.38 1.67 2.08 0.04646 2,966.6 15
1981 2.46 1.77 2.06 2.32 0.05313 2,993.0 15
1982 3.20 2.03 2.55 3.10 0.06625 3,026.0 16
1983 3.22 2.44 2.86 2.55 0.06750 3,061.3 14
1984 2.68 1.75 2.16 2.26 0.07375 2,925.5 14
1985 3.45 2.20 2.78 3.29 0.08000 2,925.6 15
1986 4.64 2.86 3.97 4.10 0.08625 2,765.6 43
1987 6.59 3.44 5.28 4.68 0.10063 2,753.5 17
1988 5.51 4.35 5.06 5.32 0.12000 2,664.6 16
1989 7.44 5.19 6.25 7.42 0.14000 2,679.4 19
1990 9.27 6.39 7.85 8.97 0.16375 2,700.4 21
1991 14.53 8.17 11.19 14.31 0.19250 2,713.4 30
1992 14.67 10.75 12.34 12.63 0.22250 2,674.2 23
1993 12.60 8.91 10.50 11.22 0.25250 2,627.8 17
1994 14.13 9.00 11.54 13.69 0.28250 2,645.0 19
1995 23.10 13.41 17.19 21.38 0.32000 2,665.6 25
17
Johnson & Johnson and Subsidiaries:
Common Stock Information 1944-2013 (Price per share/Shares in Millions)
YEARLY YEARLY YEARLY YEAR-END YEARLY NET SHARES P/E
YEAR HIGH LOW AVERAGE PRICE DIVIDEND OUTSTANDING* RATIO
1996 27.00 20.78 24.29 24.88 0.36750 2,753.4 25
1997 33.66 24.32 29.82 32.97 0.42500 2,971.6 32
1998 44.88 31.69 37.46 41.94 0.48500 2,975.3 41
1999 53.44 38.50 46.99 46.63 0.54500 2,979.6 34
2000 52.97 33.07 44.64 52.53 0.62000 3,014.6 33
2001 60.97 40.25 51.88 59.86 0.70000 3,047.2 34
2002 65.89 41.40 57.67 53.11 0.79500 2,968.3 25
2003 59.08 48.05 52.62 50.62 0.92500 2,967.9 22
2004 64.25 49.25 55.84 63.42 1.09500 2,971.0 23
2005 64.60 59.76 64.70 60.10 1.27500 2,971.0 18
2006 69.41 56.70 62.21 66.02 1.45500 2,893.2 18
2007 68.75 59.72 63.98 67.38 1.62000 2,840.2 18
2008 72.76 52.06 64.91 58.56 1.79500 2,769.2 13
2009 65.41 46.25 56.88 64.41 1.93000 2,754.3 15
2010 66.20 56.86 62.16 61.85 2.11000 2,738.1 13
2011 68.05 57.50 63.56 65.58 2.25000 2,724.4 19
2012 72.74 61.71 66.95 69.48 2.40000 2,778.5 18
2013 95.99 69.18 85.65 92.35 2.59000 2,820.6 19
* Net shares outstanding = shares issued less treasury stock at Johnson & Johnson year-end close.
Note: All data adjusted for prior stock splits; shares outstanding are actual J&J year-end close; year -end share price per
Yahoo Finance at J&J year-end close; P/E ratio based on fiscal year-end closing price.
18
Johnson & Johnson and Subsidiaries:
Reconciliation of Non-GAAP Measures (Dollars in Millions except per share amounts)
2013 2012 2011 2010 2009
Earnings before provision for taxes on income- as reported 15,471 $ 13,775 12,361 16,947 15,755
Net litigation loss (gain) 2,282 1,229 3,310 (397) (386)
Intangible asset write-downs - 939 - - -
Restructuring expense - - 656 - 1,186
DePuy ASR
TM
Hip program 251 110 521 280 -
Synthes integration/transaction costs and currency related 683 1,028 491 - -
In-process research & development (IPR&D)
(1)
580 1,163 14 - -
Other (98) (30) - - -
Earnings before provision for taxes on income- as adjusted 19,169 $ 18,214 17,353 16,830 16,555
Net Earnings
(2)
- as reported 13,831 $ 10,853 9,672 13,334 12,266
Net litigation loss (gain) 1,646 1,052 2,745 (294) (212)
Intangible asset write-downs - 717 - - -
Restructuring expense - - 536 - 852
DePuy ASR
TM
Hip program 240 97 426 239 -
Synthes integration/transaction costs and currency related 483 899 477 - -
In-process research & development (IPR&D)
(1)
462 743
(3)
11 - -
Scios Tax Benefit (707) - - - -
Other (79) (16) - - -
Net Earnings
(2)
- as adjusted 15,876 $ 14,345 13,867 13,279 12,906
Diluted net earnings per share
(2)
- as reported 4.81 $ 3.86 3.49 4.78 4.40
Net litigation loss (gain) 0.57 0.37 0.99 (0.11) (0.08)
Intangible asset write-downs - 0.26 - - -
Restructuring expense - - 0.19 - 0.31
DePuy ASR
TM
Hip program 0.08 0.03 0.16 0.09 -
Synthes integration/transaction costs and currency related 0.17 0.32 0.17 - -
In-process research & development (IPR&D)
(1)
0.16 0.27 - - -
Scios Tax Benefit (0.25) - - - -
Other (0.02) (0.01) - - -
Diluted net earnings per share
(2)
- as adjusted 5.52 $ 5.10 5.00 4.76 4.63
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on
income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations. These non-GAAP financial
measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
(1) In 2009, in accordance with U.S. GAAP for business combinations, purchased in-process research and development is no longer expensed, but capitalized and
tested for impairment.
(3) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to
noncontrolling interest
(2) Attributable to J ohnson & J ohnson
19

Principal Office
One J ohnson & J ohnson Plaza
New Brunswick, New J ersey 08933
(732) 524-0400

Common Stock
Listed on New York Stock Exchange
Stock Symbol: J NJ

Annual Meeting
The Annual Meeting of Shareholders will take
place on Thursday, April 24, 2014, at the
Hyatt Regency Hotel, Two Albany Street, New
Brunswick, New J ersey. The meeting will
convene at 10 a.m. All shareholders as of the
record date of February 25, 2014 are cordially
invited to attend. A formal Notice of Annual
Meeting, Proxy Statement and Proxy have
been sent to shareholders.

Transfer Agent and Registrar
Questions regarding stock holdings, certificate
replacement/transfer, dividends and address
changes should be directed to:
Computershare Trust Company, N.A.
250 Royall St.
Canton, MA 02021
(800) 328-9033 or
(781) 575-2718 (outside the U.S.)
www.computershare.com
Dividend Reinvestment Plan
The Plan allows for full or partial dividend
reinvestment and additional monthly cash
investments up to $50,000 per year in
J ohnson & J ohnson Common Stock without
brokerage commissions or service charges on
stock purchases. If you are interested in
participating in the Plan and need an
authorization form and/or more information,
please call Computershare Trust Company,
N.A. at (800) 328-9033 or (781) 575-2718
(outside the U.S.).

Shareholder Relations Contact
Douglas K. Chia
Corporate Secretary
(732) 524-2455


Investor Relations Department
One J ohnson & J ohnson Plaza
New Brunswick, New J ersey 08933
1-800-950-5089
Fax: (732) 524-3867
Louise Mehrotra
Vice President, Investor Relations
(732) 524-6492
Stan Panasewicz
Senior Director, Investor Relations
(732) 524-2524

Lesley Fishman
Senior Director, Investor Relations
(732) 524-3922
Sue Hohenleitner
Senior Director, Investor Relations
(732) 524-3709
Lisa Romanko
Senior Director, Investor Relations
(732) 524-2034
Renee McKenna
Senior Analyst
(732) 524-6492

Reports Available
Copies of the Company's 2013 Annual
Report on Form 10-K, Quarterly Reports on
Form 10-Q and Current Reports on Form
8-K to the Securities and Exchange
Commission, Proxy Statement and the
Annual Report are available online
at www.jnj.com or to shareholders without
charge upon written request to the
Secretary at the Company's principal
address or by calling (800) 328-9033 or
(781) 575-2718 (outside the U.S.)
Press Releases
Press releases, including earnings
reports, are available via web
access http://www.jnj.com
Internet Access
Visit the J ohnson & J ohnson Home
Page on the
Internet: http://www.jnj.com

J ohnson & J ohnson 2013
Trademarks and service marks of J ohnson & J ohnson and its affiliated
companies are designated by all capital letters in this publication

Corporate and Shareholder/Investor Information

20
2013





Descr iption
Through its family of companies, the worlds most comprehensive and
broadly based manufacturer of health care products
Serves the Consumer, Pharmaceutical and Medical Devices and
Diagnostics markets by developing broadly accessible, high quality,
innovative products and services that advance the health and well-being
of people

Consistent Perfor mance
30 consecutive years of earnings increases adjusted for special items
51 consecutive years of dividends increases

One Year
2
Five Years
2
Ten Years
2

Sales 6.1% 2.3% 5.5%
Diluted Adjusted Earnings per
Share
1

8.2% 3.9% 8.1%
Dividend Growth 7.9% 7.6% 10.8%
Total Return to Shareholders 34.6% 12.6% 8.9%
1
Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports.
2
Compounded Annual Growth Rates

Broadly Based/ Excepti onal Financial Str ength
Over 275 operating companies in 60 countries selling products
throughout the world (approximately 55% of sales outside of U.S.)
Sales split among Consumer, Pharmaceutical and Medical Devices and
Diagnostics business segments
More than 100 drugs marketed; 41 drugs over $50 million; 32 drugs over
$100 million; 8 drugs over $1 billion
One of four U.S. industrial companies that still commands a Triple A
credit rating by both Standard & Poors and Moodys credit rating
agencies
Generated annual free cash flow
1
in 2013 of $13.8 billion.

1
Non-GAAP financial measure; defined as operating cash flow less capital spending





















(1) Net Earnings attributable to Johnson & Johnson























Wor ldwide Market Leadershi p
Largest Medical Device company
7
th
largest Pharmaceutical company
globally
6
th
largest Biotech company globally
6
th
largest Consumer Health Care
company globally
Leadership Positions in Major Markets:
Antithrombotic agents
Antipsychotics (Injectables)
Anti - TNF
Baby Care
Biosurgicals
Blood Glucose Monitoring
Breast Aesthetics
Disposable Contact Lenses
Electrophysiology diagnostics
& catheters
Hormone antagonists
Infection Prevention
Lo-Cal Sweeteners
Minimally Invasive Surgery
Oral Rinses
Orthopaedics
OTC Analgesics
Sanitary Protection
Sutures
Systemic Antipsoriasis
products
Wound Care
Approximately 70% of sales are derived
from products/businesses that have a
#1 or #2 global market share position












2013 Worldwide
Sales $71.3 Billion
2013
Investor
Fact Sheet

Approximatel y
##%
Please visit our Home Page on the Internet at
http://www.jnj.com for requests for Company
Reports, including the 2013 Annual Report
and SEC filings. Questions regarding stock
holdings and the Dividend Reinvestment
Plan, should be directed to: Computershare
Trust Company,N.A. Phone (800) 328-9033
2003

$6,848
2008

Net Earnings
(1)
(as reported)

$U.S. Millions $12,949
$13,831
Approximatel y
25%
New Products Introduced
in Past 5 Years

21



























































Strong Commitment to New
Product Development
$8.2 billion in Research &
Development expense in 2013
Numerous external alliances and
collaborations entered into
annually
Approximately 25% of products
sold in 2013 introduced in last 5
years


Management Based on a Cor e Set
of Strategi c Pr inciples
Creating Value through Innovation
o Robust pipeline of new and
innovative products
Global Reach/Local Focus
o Broad geographic reach
provides ability to rapidly
introduce new products in
markets around the world
Excellence in Execution
o Maintaining high quality
products and standards
Leading with a Purpose
o Focus on products which
increase access, reduce cost and
improve the quality of health
care


I nvestor I nfor mation

NYSE Symbol: J NJ

For additional i nfor mation,
contact:
Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Voice: (800) 950-5089
Fax: (732) 524-3867

Press releases, including earnings
reports, are available via web access:
http://www.jnj.com


$18.6
$7.4
$13.4
$31.9
80
105
130
155
180
205
230
2003 2005 2007 2009 2011 2013
D
O
L
L
A
R
S
J ohnson & J ohnson
S&P 500
S&P Pharm
S&P H/C Equip
2013 Sales by Geographic
Area
$U.S. Billions

Shareholder Return Comparison
$100 Dollars invested December 31, 2003
This chart provides a comparison of cumulative total shareholder return for an
investment in Johnson & Johnson Common Stock as of December 31, 2013 to a similar
investment in the identified indices. Assuming dividends were reinvested, a $100.00
investment in Johnson & Johnson would have grown to $235.59 as of December 31, 2013.
This compares to a value of $204.26 for the S&P 500 Stock Index, $193.25 for the S&P
Pharmaceutical Index and $166.10 for the S&P Healthcare Equipment Index.
Source: Bloomberg
Europe
U.S.
Western
Hemisphere
Asia-Pacific
Africa
45%
26%
10%
19%
$28.5
$28.1
$14.7
2013 Sales by Segment
$U.S. Billions
21% 40%
39%
MD&D
Pharmaceutical
Consumer
International
U.S.
Net Trade Sales
$U.S. Billions
2003 2008 2013
Johnson & Johnson 2013
$71.3
$63.7
$41.9
22